FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384701622> ?p ?o ?g. }

• W4384701622 endingPage "686" @default.
• W4384701622 startingPage "663" @default.
• W4384701622 abstract "Prostate cancer is a leading cause of cancer death in men worldwide. Among the various treatment options, radiopharmaceutical therapy has shown notable success in metastatic, castration-resistant disease. Radiopharmaceutical therapy is a systemic approach that delivers cytotoxic radiation doses precisely to the malignant tumors and/or tumor microenvironment. Therapeutic radiopharmaceuticals are composed of a therapeutic radionuclide and a high-affinity, tumor-targeting carrier molecule. Therapeutic radionuclides used in preclinical prostate cancer studies are primarily α-, β--, or Auger-electron-emitting radiometals or radiohalogens. Monoclonal antibodies, antibody-derived fragments, peptides, and small molecules are frequently used as tumor-targeting molecules. Over the years, several important membrane-associated proteases and receptors have been identified, validated, and subsequently used for preclinical radiotherapeutic development for prostate cancer. Prostate-specific membrane antigen (PSMA) is the most well-studied prostate cancer-associated protease in preclinical literature. PSMA-targeting radiotherapeutic agents are being investigated using high-affinity antibody- and small-molecule-based agents for safety and efficacy. Early generations of such agents were developed simply by replacing radionuclides of the imaging agents with therapeutic ones. Later, extensive structure-activity relationship studies were conducted to address the safety and efficacy issues obtained from initial patient data. Recent regulatory approval of the 177Lu-labeled low-molecular-weight agent, 177Lu-PSMA-617, is a significant accomplishment. Current preclinical experiments are focused on the structural modification of 177Lu-PSMA-617 and relevant investigational agents to increase tumor targeting and reduce off-target binding and toxicity in healthy organs. While lutetium-177 (177Lu) remains the most widely used radionuclide, radiolabeled analogs with iodine-131 (128I), yttrium-90 (89Y), copper-67 (67Cu), and terbium-161 (161Tb) have been evaluated as potential alternatives in recent years. In addition, agents carrying the α-particle-emitting radiohalogen, astatine-211 (211At), or radiometals, actinium-225 (225Ac), lead-212 (212Pb), radium-223 (223Ra), and thorium-227 (227Th), have been increasingly investigated in preclinical research. Besides PSMA-based radiotherapeutics, other prominent prostate cancer-related proteases, for example, human kallikrein peptidases (HK2 and HK3), have been explored using monoclonal-antibody-(mAb)-based targeting platforms. Several promising mAbs targeting receptors overexpressed on the different stages of prostate cancer have also been developed for radiopharmaceutical therapy, for example, Delta-like ligand 3 (DLL-3), CD46, and CUB domain-containing protein 1 (CDCP1). Progress is also being made using peptide-based targeting platforms for the gastrin-releasing peptide receptor (GRPR), a well-established membrane-associated receptor expressed in localized and metastatic prostate cancers. Furthermore, mechanism-driven combination therapies appear to be a burgeoning area in the context of preclinical prostate cancer radiotherapeutics. Here, we review the current developments related to the preclinical radiopharmaceutical therapy of prostate cancer. These are summarized in two major topics: (1) therapeutic radionuclides and (2) tumor-targeting approaches using monoclonal antibodies, small molecules, and peptides." @default.
• W4384701622 created "2023-07-20" @default.
• W4384701622 creator A5001228741 @default.
• W4384701622 creator A5029810995 @default.
• W4384701622 creator A5049568817 @default.
• W4384701622 creator A5067187971 @default.
• W4384701622 creator A5092495216 @default.
• W4384701622 date "2023-09-01" @default.
• W4384701622 modified "2023-10-12" @default.
• W4384701622 title "Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer" @default.
• W4384701622 cites W1963575875 @default.
• W4384701622 cites W1972701704 @default.
• W4384701622 cites W1973269553 @default.
• W4384701622 cites W1975602223 @default.
• W4384701622 cites W1982551773 @default.
• W4384701622 cites W1982769477 @default.
• W4384701622 cites W1986689451 @default.
• W4384701622 cites W1995042145 @default.
• W4384701622 cites W2002384741 @default.
• W4384701622 cites W2016200341 @default.
• W4384701622 cites W2016973566 @default.
• W4384701622 cites W2019490921 @default.
• W4384701622 cites W2028392455 @default.
• W4384701622 cites W2030940240 @default.
• W4384701622 cites W2038578630 @default.
• W4384701622 cites W2046842891 @default.
• W4384701622 cites W2053978050 @default.
• W4384701622 cites W2060695118 @default.
• W4384701622 cites W2115158465 @default.
• W4384701622 cites W2120171756 @default.
• W4384701622 cites W2137571973 @default.
• W4384701622 cites W2140698185 @default.
• W4384701622 cites W2142421794 @default.
• W4384701622 cites W2155421560 @default.
• W4384701622 cites W2170794639 @default.
• W4384701622 cites W2171140185 @default.
• W4384701622 cites W2175765437 @default.
• W4384701622 cites W2269069739 @default.
• W4384701622 cites W2281156288 @default.
• W4384701622 cites W2287576637 @default.
• W4384701622 cites W2316959840 @default.
• W4384701622 cites W2403516958 @default.
• W4384701622 cites W2467018059 @default.
• W4384701622 cites W2504946646 @default.
• W4384701622 cites W2511314637 @default.
• W4384701622 cites W2516134533 @default.
• W4384701622 cites W2593925322 @default.
• W4384701622 cites W2595075592 @default.
• W4384701622 cites W2605070587 @default.
• W4384701622 cites W2610081635 @default.
• W4384701622 cites W2611673620 @default.
• W4384701622 cites W2776398258 @default.
• W4384701622 cites W2786988345 @default.
• W4384701622 cites W2795555192 @default.
• W4384701622 cites W2799487694 @default.
• W4384701622 cites W2799908504 @default.
• W4384701622 cites W2802125673 @default.
• W4384701622 cites W2887229904 @default.
• W4384701622 cites W2892222776 @default.
• W4384701622 cites W2892869908 @default.
• W4384701622 cites W2898623933 @default.
• W4384701622 cites W2899588790 @default.
• W4384701622 cites W2905255192 @default.
• W4384701622 cites W2906948885 @default.
• W4384701622 cites W2909736464 @default.
• W4384701622 cites W2920085931 @default.
• W4384701622 cites W2940075529 @default.
• W4384701622 cites W2942632852 @default.
• W4384701622 cites W2944699890 @default.
• W4384701622 cites W2947948130 @default.
• W4384701622 cites W2954206886 @default.
• W4384701622 cites W2963473092 @default.
• W4384701622 cites W2963700677 @default.
• W4384701622 cites W2968654070 @default.
• W4384701622 cites W2969664332 @default.
• W4384701622 cites W2979379111 @default.
• W4384701622 cites W2991026793 @default.
• W4384701622 cites W2996077865 @default.
• W4384701622 cites W3005700110 @default.
• W4384701622 cites W3008344257 @default.
• W4384701622 cites W3015229102 @default.
• W4384701622 cites W3020771563 @default.
• W4384701622 cites W3021909379 @default.
• W4384701622 cites W3023519405 @default.
• W4384701622 cites W3033603848 @default.
• W4384701622 cites W3039594694 @default.
• W4384701622 cites W3041016676 @default.
• W4384701622 cites W3045665740 @default.
• W4384701622 cites W3082635082 @default.
• W4384701622 cites W3087151197 @default.
• W4384701622 cites W3093268796 @default.
• W4384701622 cites W3094362710 @default.
• W4384701622 cites W3108377814 @default.
• W4384701622 cites W3108380802 @default.
• W4384701622 cites W3111903169 @default.
• W4384701622 cites W3112041870 @default.
• W4384701622 cites W3118282594 @default.
• W4384701622 cites W3120206025 @default.

• next